摘要
目的:探究瑞舒伐他汀钙片联合依折麦布片对冠心病患者糖脂代谢水平的影响。方法:选择2018年10月至2019年10月入住我院的98例冠心病患者为研究对象,按随机数表分为试验组和对照组(n=49)。对照组患者口服依折麦布片10 mg Qd进行治疗,试验组在此基础上口服瑞舒伐他汀钙片10 mg Qd治疗。比较治疗前与治疗4 w后患者血脂水平变化,包括总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)水平,并分析患者治疗4 w后的有效率与药物不良反应发生率。结果:治疗4 w后,试验组治疗有效率明显高于对照组(P<0.05);两组患者TC、TG、LDL-C水平较治疗前均显著降低,且试验组明显低于同一时间对照组(P<0.05);HDL-C水平较治疗前均显著升高,且试验组明显高于同一时间对照组(P<0.05)。治疗4 w内,试验组患者药物不良反应总发生率明显低于对照组(P<0.05)。结论:瑞舒伐他汀钙片联合依折麦布片对冠心病患者糖脂代谢水平具有明显改善作用,疗效显著,安全性高,利于预后。
Objective:To explore the effect of rosuvastatin calcium tablets combined with ezeimibo tablets on glucose and lipid metabolism in patients with coronary heart disease.Methods:A total of 98 patients with coronary heart disease admitted to our hospital from October 2018 to October 2019 were selected as the study objects.According to the random number table,they were divided into the experimental group and the control group with 49 cases each.The patients in the control group were treated with yizhemebu tablet(10 mg Qd),while the patients in the experimental group were treated with rosuvastatin calcium tablet(10 mg Qd)on the basis of the control group.Before and after 4 weeks of treatment,the changes of blood lipid level(Total cholesterol,TC;Triglyceride,TG;Low density lipoprotein cholesterol,LDL-C;High density lipoprotein cholesterol,HDL-C)of patients were compared.The effective rate of treatment and the incidence of adverse drug reactions within 4 weeks were analyzed.Results:After 4 weeks of treatment,the effective rate of treatment in the experimental group was significantly higher than that in the control group(P<0.05).The levels of TC,TG and LDL-C in the two groups were significantly lower than those before treatment,and the levels of HDL-C in the experimental group were significantly lower than those in the control group at the same time(P<0.05).The levels of HDL-C in the experimental group were significantly higher than those in the control group at the same time(P<0.05).Within 4 weeks,the total incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion:Rosuvastatin calcium tablets combined with ezeimaibu tablets can significantly improve the level of glucose and lipid metabolism in patients with coronary heart disease,with significant efficacy,high safety and favorable prognosis.
作者
牛圣
Niu Sheng(Nanyang Second People's Hospital,Nanyang 473000,Henan,China)
出处
《四川生理科学杂志》
2021年第2期236-238,共3页
Sichuan Journal of Physiological Sciences
关键词
瑞舒伐他汀钙片
依折麦布片
冠心病
糖脂代谢水平
Rosuvastatin calcium tablet
Yizomaibu tablet
Coronary heart disease
Glucose and lipid metabolism level
